tbuckley/cabot-search huggingface dataset:
Survey on current status of type 2 diabetes management in Nanjing at grassroots level
Authors: Kuo Li, Xianghua Sun, Dexian Mei, Man Li, Yanwei Feng, Dandan Liu, Qianyun Ji, Yun Hu
Journal: BMJ (2019)

From September to October 2018, a questionnaire survey was conducted on the status of diabetes management, basic equipment allocation, complication screening and follow-up, basic drug supply and health education among 136 grassroots institutions in Nanjing. Doctors in the 136 grassroots institutions who had received diabetes specialist training accounted for 18.2% (358/1 968) of total general practitioners. The management rate of diabetes patients was 98.67% (196 352/199 000) , and the standard management rate was 88.63%(174 024/196 352).The screening and follow-up rates of diabetic complications were 89.0%(121/136) and 61.2%(74/121) for glycosylated hemoglobin; 64.7%(88/136), 58.0%(51/88) for urine microalbumin;51.5% (70/136), 62.9%(44/70) for diabetic foot; 44.9%(61/136), 42.6%(26/61) carotid ultrasonography; 32.4%(44/136) and 59.1%(26/44) for fundus examination; 17.6%(24/136) and 33.3%(8/24) for ankle brachial index. The rates of screening for glycosylated hemoglobin, urinary microalbumin, diabetic foot, carotid B ultrasound, fundus and ankle brachial index in urban areas were significantly higher than those in the suburbs (both P<0.05). The diabetes health education was regularly conducted in 92.0%(126/136) of grassroots institutions. At present, the grassroots institutions in Nanjing have established health archives for most diabetic patients and conducted health education regularly, but the professional training and the screening of diabetic complications need to be strengthened.


Key words: 
Community health services; Diabetic mellitus, type 2; Questionnaires
心包大量积液确诊为恶性间皮瘤一例
Authors: 王启贤, 梁晓东
Journal: BMJ (2008)

患者女,30岁,主诉胸痛1个月,胸闷15 d.患者1个月前无明显诱因感胸痛,位于胸骨下段剑突处呈针刺样持续疼痛,并向肩背部放射,于深吸气和左侧卧位时加剧.无低热、盗汗、咳嗽、咯血、消瘦等,也无纳差、怕冷、少言懒动、表情淡漠等.15 d前开始出现胸闷、气促、乏力、夜间阵发性呼吸困难,伴干咳、腹胀、恶心,无呕吐、腹泻等.到当地市医院就诊,行B超后确诊为大量心包积液,未经治疗转入我院。
三里屯医院全科医疗科出诊情况分析
Authors: 王玉霞, 鲁淑梅, 杜娟, 康娜, 杨颖, 曹硕
Journal: BMJ (2005)

北京市朝阳区三里屯地区面积2.9 km2,常住人口5万余人.区内惟一的一级医院即北京市朝阳区三里屯医院,始建于1957年7月,在三里屯地区下设2个社区卫生服务站.自2000年始,由医院和下辖社区卫生服务站共同承担所在地区的基本医疗和预防保健等社区卫生服务.现就三里屯医院全科医疗科2000年1月1日至2003年12月31日的出诊情况报告如下。
Posterior reversible encephalopathy syndrome:report of six cases
Authors: Mei-yan Liao, Zhi-xiong Tian, Xiong Huang
Journal: BMJ (2008)

Objecfive To investigate clinical features and imaging manifestation in patients with posterior reversible eneephalopathy syndrome (PRES) to improve its recognition.Methods Six patients with PRES were enrolled,four women with history of end-stage renal disease,kidney transplantation,eclampsia,or systemic lupus erythematosus (SLE) and two men with history of chemotherapy or hypertension.All of them underwent multi-serial MR imaging (T1 WI,T2 WI,FLAIR) and post-contrast T1 WI.Three cases also underwent CT scan and gadolinium enhancement. Results All the six cases of PRES had different inducing causes such as acute hypertension,preeclampsia or eclampsia, taking immunosuppressive agents or steroids.and their clinical symptoms were characterized by sudden occurrence of headache,eclampsia or seizure of epilepsy,altered melltal status,visual disturbances.Clinical symptoms were died out in about one week after prompt and appropriate treatments for high blood pressure.or removal of precipitating factors,or treatment for epileptic seizures or status epilepticus.MRI and CT scanning demonstrated multifocal subcortical white lesions in bilateral parieto-occipital lobes (six cases), bilateralfrontal lobes (two cases),bilateral post temporal lobes (two cases) and left cerebellum (one cases).and cortical involvement (two cases).All lesions appeared unenhanced with gadolinium enhancement. FoHow-up by MRI showed decreased abnormal signs and small infarct foci were left in the cortex-subeortex of one case.Conclusions PRES is a clinico-neuroradiologieal transient condition, usually benign and reversible in nature.Completely clinical and radiographic recovery Can be achieved with prompt antihypertensive treatment or removal of precipitating factors and supportive care,but delayed diagnosis and therapy Can result in cerebral infarct with neurological sequelae.

Key words: 
Brain diseases;  Magnetic resonance imaging;  Tomography, x-rav eomvuted
Mechanisms of skin toxicity of paclitaxel: An in vitro preclinical assessment.
Authors: Jose Alejandro Perez-Fidalgo, Cristina Estornut Navarro, Celia Sanz Garcia, Martin Perez-Leal, Jesus Poveda Ferriols, Andres Cervantes, Javier Milara Paya, Julio Cortijo Gimeno
Journal: Journal of Clinical Oncology (2020)

e15511 Background: Paclitaxel skin toxicity is a frequent side effect extensively evaluated in the clinical setting. However little is known about the preclinical mechanisms that lead to this toxicity. The endpoint of this study was to analyse the cutaneous mechanisms that drive paclitaxel toxicity in a preclinical model. Methods: Primary human keratinocytes were co-cultured with human dermal fibroblast in collagen gel under air-liquid interface conditions to generate a multilayered 3D epidermis. Paclitaxel was added to 3D epidermis at 0.3 µM, 3 µM and 30 µM and total RNA and protein was extracted after 24h of incubation. Markers of cell senescence (p21 and p53), anti-apoptotic mediators (Bcl-2), skin elasticity (tropoelastin ELN, collagen type I and fibronectin), hidratation (aquaporin 3 AQP3), oxidative stress (NOX4), antioxidant (SOD1, Nrf2), and angiogenic markers (VEGFR, eNOS) were evaluated by RT-PCR and western blot. NfKB phosphorylation was measured by western blot and inflammatory citokines IL1α, IL-6 and IL-8 were measured in cultured supernatants by ELISA. Human primary melanocytes were cultured and stimulated with paclitaxel to measure melanogenesis through the expression of of TYR, TYRP1 and DCT genes. The effect of paclitaxel on skin endothelial cell angiogenesis was measured by endothelial tube formation. Results: In human 3D keratinocytesPaclitaxel inhibited the expression of Bcl-2, and increased the expression of p53 and p21. The angiogenic markers VEGF and eNOS were decreased. The expression of oxidative stress marker NOX4 was increased and the anti-oxidant mediators Nrf2 and SOD1 were decreased. Markers of elasticity, collagen type I, fibronectin and FN1 were decreased as occurs with AQP3 hidratation marker. Paclitaxel increased the phosphorylation of NfkB and elevated the secretion of IL1α, IL-6 and IL-8 cytokines. In skin endothelial cells, paclitaxel reduced the endothelial tube formation. In melanocytes, paclitaxel increased skin pigmentation represented by the increase of RNA expression of TYR, TYRP1 and DCT genes. Conclusions: This preclinical 3D model showed that paclitaxel impacts on the expression of proteins related with angiogenics, elasticity and senescence in human kerantinocytes. Moreover higher doses of paclitaxel increased inflammation parameters and confirmed phototoxic and anti-angiogenenic effects. This preclinical model could be a valuable tool to assess skin toxicity of new antineoplastic agents.
尿道灌注治疗男性非淋菌性尿道炎101例
Authors: 邓镇和, 章东
Journal: BMJ (2006)

将186例非淋菌性尿道炎患者随机分为治疗组101例,从尿道内灌注左氧氟沙星+口服阿奇霉素;对照组85例,口服左氧氟沙星及阿奇霉素.结果表明,治疗组和对照组总有效率分别为93.1%、84.7%,两组比较差异无统计学意义(χ2=3.36,P>0.05),痊愈率分别为82.2%、55.3%,两组比较差异有统计学意义(χ2=12.72,P<0.01)。
Progress of nationwide promotion of Chinese guideline for primary care of cough at grass-roots level
Authors: Kefang Lai
Journal: BMJ (2019)

咳嗽是基层医疗机构患者最常见的主诉，但大量患者被误诊误治，并造成抗菌药物的滥用。结合基层医院的特点和需求，首次制定了中国《咳嗽基层诊疗指南（2018年）》，主要内容包括急性咳嗽、亚急性咳嗽、慢性咳嗽的常见病因及诊治以及咳嗽的经验性治疗等，同时特别增加了患者转诊到上级医院的指征，以期进一步促进咳嗽诊治的规范化，提高中国基层医疗机构的咳嗽诊治水平。
Immune infiltration and angiogenesis as markers of outcome in the post-nephrectomy setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).
Authors: A. Ari Hakimi, Martin H Voss, Fengshen Kuo, Andrew W. Silagy, Mahtab Marker, Albert Reising, John Millholland, Timothy An-thy Chan, Paul Russo, Robert J. Motzer
Journal: Journal of Clinical Oncology (2020)

5082 Background: Defined stromal and immune features of the tumor microenvironment (TME) have proven relevant for outcomes with systemic therapy in advanced clear cell renal cell carcinoma (ccRCC). We hypothesized that these may matter beyond therapeutic applications and could be relevant much earlier in the disease course. We sought to study the TME in high risk ccRCC patients undergoing definitive surgery. Methods: Clinical, pathologic, immunohistochemical, and whole-genome microarray data were acquired on 236 out of 769 patients in the Placebo arm of PROTECT trial (NCT01235962 - pazopanib vs placebo). Transcriptomic scores assessing angiogenesis and myeloid infiltration with individual annotations above/below median were used to categorize patients into four groups (angiogenesis high vs. low; myeloid high vs. low). We tested categorical association with disease free (DFS) and overall survival (OS) using logrank testing and assessed interdependence with relevant clinicopathologic variables, including the UCLA Integrated Staging System (UISS) in a cox regression model. Results: Tumors from236 patients were available for analysis. Overall, 37% developed metastatic recurrence and 81% were alive at last follow up. On univariate analysis increasing tumor stage, higher UISS score, and angiogenesis/myeloid subgroups (high – H and low – L) were associated with worse DFS and OS (all p values &lt;0.05). On multivariate analysis TME subgroups remained significant for worse DFS and OS (Table). Conclusions: Microenvironmental subgroups stratified into angiogenic and myeloid expression profiles carry independent prognostic significance and should be further explored to guide future biomarker-directed adjuvant trials. Clinical trial information: NCT01235962 . [Table: see text]
Clinical analysis of venous thromboembolic disease during puerperium
Authors: Ming-yao Luo, Chang Shu, Quan-ming Li, Xiao-hua Jiang, Ming Li
Journal: BMJ (2011)

Thirty seven patients with venous thromboembolic disease in puerperium were admitted to hospital from January 2005 to December 2008; the clinical data of patients were retrospectively analyzed.The average age of patients was (33 ± 6)years (21 -42 years); the average onset time was ( 10 ± 6) d( 1 -50 d) after delivery.Seven patients had vaginal birth and 30 by cesarean section.The risk factors included pregnancy,cesarean section,age,infection,thrombophilia.All were diagnosed by ultrasonography and treated by anticoagulant,antiplatelet and thrombolytic therapy in the acute phase,followed by wearing elastic compressive stockings for more than 2 years.Pulmonary embolism was diagnosed in 8 patients by CT angiography,in 7 of whom inferior vena cava filter was administrated emergently.The patients were followed up for (29 ± 10)months ( 12 -60 months); during the follow-up 3 developed deep vein post-thrombosis syndrome,while others kept in good condition.The results indicate that initial anticoagulant,antiplatelet and thrombolytic therapy followed by elastic compressive stockings administration is effective for venous thromboembolic disease during puerperium.

Key words: 
Postpartum period; Venous thrombosis
妊娠晚期自发性肝破裂一例
Authors: 陈芹, 路运珍
Journal: BMJ (2009)

患者35岁,女性.因停经8个月余,头晕胸闷半天于2008年12月10日入院.患者既往月经规律,末次月经2008年4月15日,预产期2009年1月22日.患者孕40余天时出现恶心、呕吐等早孕反应,持续月余消失.孕4个月余时出现胎动,孕期基本顺利.半月前上呼吸道感染咳嗽,在当地医院给予抗炎治疗,具体用药不详。
Performance of neoadjuvant therapy in locally advanced adenocarcinoma of the pancreas: A single large volume center experience.
Authors: Teresa Lee, Tingting Zhan, Subikram Chanda, Adam Barsouk, David Nauheim, Bryan Renslo, Mandeep Shergill, Wei Jiang, Timothy Chao, Harish Lavu, Charles Yeo, James Posey
Journal: Journal of Clinical Oncology (2020)

e16745 Background: Pancreatic adenocarcinoma (PC) is a disease with low 5-year survival rates even in patients who undergo surgical resection: ~10% overall and 20-35% in those with negative lymph nodes and R0 operation. Adjuvant chemotherapy (CT) has demonstrated benefit; however, not all patient are candidates for multi-agent CT post-op. Early use of systemic therapy might improve outcomes. As a leading referral center for pancreatic resection in a tri-state area, we present a single institution real-world experience of neoadjuvant CT (neo-CT) in PC patients principally with degrees of vascular abutment at presentation. Methods: We identified 90 patients scheduled for pancreatectomy from 2015 to 2019 who received neo-CT. Three had an aborted procedure due to occult metastatic disease. Of those who underwent resection (n = 87), most were borderline or locally advanced (n = 79) with a few deemed resectable (n = 5) or metastatic (n = 3) prior to CT. 80 patients (92%) had R0 resection, though final pathology showed R1 resection in 5 and distant metastases in 2 patients. 72% of patients (n = 63) received 5-FU-based neo-CT, while 28% (n = 24) received gemcitabine-based CT. 36% (n = 31) received neoadjuvant radiation (RT) (with or without concurrent CT) in addition to CT, and 43% (n = 37) had adjuvant therapy, either CT, RT, or a combination. 4 patients received additional therapies on clinical trial. 41 patients (47%) completed &gt;6 months of peri-operative CT, with 23 of those (26%) completing 6 months prior to surgery. We evaluated pathologic regression scores and compared those with very good response (score 0-1) post-CT vs. partial (score 2) or no response (score 3). Results: Median progression-free survival (PFS) from start of treatment in our cohort was 1.9 years (95% CI 1.4-NR) while median overall survival (OS) was 3.0 years (95% CI 2.4-NR). Duration of neo-CT did not affect PFS or OS. Logrank tests of OS curves of the 3 pathologic response groups indicated a statistically-significant difference (p = 0.004), with longer OS in patients with score 0-1 and shorter OS in patients with score 3. Conclusions: This analysis involves patients treated in both community and academic settings. We observed improved survival among those with best pathologic responses. The majority of cases with lower residual tumor burden received FOLFIRINOX. We are analyzing molecular data in this cohort and will conduct adjusted analyses for clinical characteristics. The prospective selection of multiagent CT in PC may be influenced by molecular profile and early response assessment.
糖尿病足与周围神经病变
Authors: 许樟荣
Journal: BMJ (2007)

根据WHO的定义,糖尿病足是与局部神经异常和下肢远端外周血管病变相关的足部感染、溃疡和(或)深层组织破坏.国际糖尿病足工作组将糖尿病足溃疡定义为糖尿病患者踝以下的累及全层皮肤的创面,而与这种创面的病程无关.糖尿病足溃疡和坏疽有时发展十分迅速,如不及时转诊给专科医生处理,可能会造成严重后果.因此对于非专科医生而言,及时发现糖尿病患者的足病,并根据其病情程度及时转诊十分重要。
Correlational study of different analgesic programs on patients' quality of life, mood, and dignity.
Authors: Long Wang, Xue Zhang, Zhimin Liu, Mei Shan, Xinyan Hu, Jing Zuo, Yudong Wang, Zhisong Fan, Yanzhi Cui, Da Jiang
Journal: Journal of Clinical Oncology (2020)

e24139 Background: To evaluate the effects between oral sustained release opioids and other analgesic drugs on the quality of life, mood and dignity of patients with cancer pain. Methods: Participants were cancer patients with cancer pain recruited from a tertiary cancer hospital in North China. Patients were divided into group A (oral sustained-release strong opioids,) and group B (non-sustained release strong opioid analgesia, as tramadol, oxycodone aminophenol, non-steroidal analgesia, etc.) to assess their quality of life, mood and dignity. Data were collected using the Patient Dignity Inventory, the MD Anderson Symptom Inventory–Chinese, the distress thermometer, the Hospital Anxiety and Depression Scale, and the 30-question core Quality of Life Questionnaire from the European Organisation for Research and Treatment of Cancer, and were analyzed using quantitative methods. Results: The study included 297 cancer pain patients, including 172 males and 125 females, with a median age of 58 years, most of whom were lung cancer (n = 88), esophageal/gastric cancer (n = 63) and colorectal cancer (n = 52). Patients in group A(n = 224) had better pain control (P &lt; 0.001), symptom burden (P &lt; 0.001), psychological distress (P &lt; 0.001), anxiety (P = 0.001) and Sense of dignity (P = 0.014) than those in group B(n = 73). In terms of quality of life assessment, patients in group A were more likely to suffer from nausea and vomiting (P = 0.003), and patients in group A were better than those in group B (Ps &lt; 0.05), except for the similarity of social cognitive function, decreased appetite, diarrhea and constipation. Conclusions: The analgesic program with oral sustained - release strong opioids for cancer pain patients not only has better analgesic effect than other programs, but also has obvious advantages in physical symptoms, psychological emotion, sense of dignity and overall quality of life.
Current and potential future applications of human stem cell models in drug development
Authors: Mark Donowitz, Jerrold R. Turner, Alan S. Verkman, Nicholas Constantine Zachos
Journal: Journal of Clinical Investigation (2020)

The use of model systems is of obvious importance for understanding human physiology and pathophysiology  However, the value of using human models for drug development has only relatively recently been appreciated  An FDA review of drug development reported that 80% to 90% of drug candidates entering phase I clinical trials fail, with the most common causes of failure being lack of efficacy and toxicity  Herein, recent advances in primary human culture models, their utility as preclinical testing platforms for drug target validation, and their importance in the future of drug discovery will be discussed
危重烧冲复合伤的临床治疗研究
Authors: 高伟, 陈为艳, 张宝泉, 王守峰, 党正杰, 杨新刚
Journal: BMJ (2011)

烧冲复合伤是同时或相继受到热能和冲击波的直接或间接作用而发生烧伤和冲击伤的复合伤.笔者于1998年1月至2010年1月收治烧冲复合伤患者26例,现将临床特点及治疗体会报告如下.一、临床资料1.一般资料:本组男21例,女5例.年龄22～68岁,平均35岁. 关键词：多处创伤
Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.
Authors: Birgit Geoerger, Eric Bouffet, James A. Whitlock, Christopher L. Moertel, Darren R. Hargrave, Isabelle Aerts, Kenneth J. Cohen, Lindsay Baker Kilburn, Karen D. Wright, Jeea Choi, Eduard Gasal, Mark W. Russo, Elizabeth Fox
Journal: Journal of Clinical Oncology (2020)

10506 Background: Low-grade gliomas (LGGs) are the most common brain tumors among children. Pediatric LGGs are often not surgically resectable and tend to demonstrate relapsed/remitting courses with current standard chemotherapy regimens. Moreover, radiation is often avoided due to its associated neurocognitive and endocrinologic sequelae. However, in pediatric patients (pts) with BRAF V600-mutant LGG, dabrafenib monotherapy has demonstrated meaningful clinical activity and acceptable tolerability (Hargrave et al, Clin Cancer Res. 2019; NCT01677741). Here we report the efficacy and safety of dabrafenib + trametinib (D+T) combination therapy in pediatric pts with previously treated BRAF V600-mutant LGG. Methods: This is a 4-part, open-label, multicenter, phase I/II study (NCT02124772). The limited dose-escalation (ESC) portion evaluated the D+T combination in pediatric pts ( &lt; 18 y) with recurrent/refractory BRAF V600-mutated solid tumors that were naive to MAPK pathway–targeted therapy. This was followed by a tumor cohort expansion (EXP), and the D+T combination was evaluated in BRAF V600-mutant LGG pts at recommended dose levels. Efficacy was determined by both investigator and independent review using the RANO criteria (for gliomas). Adverse events (AEs) were assessed per NCI-CTCAE v4.03. Results: Overall, 36 pediatric pts with LGG received D+T combination therapy (ESC, n = 16; EXP, n = 20); pooled efficacy data were available for both ESC and EXP, while LGG-specific safety data were available for EXP. At interim analysis (Aug 2019), 17 of the 20 pts in EXP remained on protocol therapy. Three pts withdrew/discontinued treatment because of AEs. Skin toxicity (95%) and pyrexia (75%) were the frequent AEs reported. No on-treatment deaths were reported. Across both ESC and EXP, the objective response rate (ORR) was 25% (95% CI, 12%–42%) per independent review (1 complete response [CR], 8 partial response [PR], 24 stable disease [SD], 2 progressive disease [PD], 1 unknown [UNK]) and 50% (95% CI, 33%–67%) per investigator review (2 CR, 16 PR, 17 SD, 1 UNK). However, ORR + SD was similar, with 92% and 97% of pts having SD or better per independent and investigator review, respectively. Conclusions: In pediatric pts with pretreated BRAF V600-mutant LGG, D+T combination therapy demonstrated clinical activity, with 92% of pts having SD or better by independent review using the RANO criteria. Pyrexia and skin toxicity were the common AEs; majority of these were low-grade and manageable. Clinical trial information: NCT02124772.
A prospective cohort study of HLA-B44 supertype as predictor of response to novel immune checkpoint combinations.
Authors: Tatiana Hernandez-Guerrero, Bernard Doger, Daniel Morillo, Victoria Casado, Manuel Domine, Jesús García Foncillas, Victor Moreno
Journal: Journal of Clinical Oncology (2020)

e15071 Background: To date there are no clear predictors of response to novel immune checkpoint inhibitor (ICI) combinations. Recent reports suggest that HLA-I (Human Leukocyte Antigen Class I) supertype B44 may predict survival to PD1(L)1 inhibition in patients with melanoma and non-small cell lung cancer (NSCLC) ( Chowell et al, Science 2018). We sought to study if this effect is exclusive for PD(L)1 inhibition alone and the impact of HLA-B44 on ICI combinations with new immunotherapeutic agents. Methods: Between 2017 and 2019, 77 patients treated across 11 different early phase clinical trials (NSCLC: 64: (83,1%); melanoma: 4: (5,2%), bladder 8 (10,4%); and one nasopharynx carcinoma), ICI-naive were prospectively evaluated for HLA-I subclass. All patients were ECOG 0 or 1 (50 and 27 respectively). Most patients had ≤ 2 metastatic sites (55: 71,4%); 24 (31,2%) patients were treated with PD(L)1 inhibitors as monotherapy, and 53 (68.8%) with PD(L)1-containing combinations including ICI and agonists such as ICOS, OX40 or GITR monoclonal antibodies. HLA-I was classified for supertypes and the variables of progression-free survival (PFS) and overall survival (OS) were compared for patients with HLA-B44+ and B44-, in both groups (monotherapy and combinations). Results: 44 patients were HLA-B44+ and 33 were negative. For patients treated with anti-PD(L)1 agents as monotherapy, those that were HLA-B44+ had a longer PFS: [medianPFS: 22,38 months (m) (95% CI: 13,39 – 31,37); vs 3,8m (95% IC: 2,05 – 5,65); p: 0,002] and OS: [median: 33,2 m (95% CI: 23,7 – 42,6) vs 14,46 m (95% IC: 7,86 – 21,1); p: 0,13]. In contrast, these marked differences were not evident in patients receiving PD1 combination therapies [HLA-B44+ mPFS: 7,17m (95% CI: 4,41 - 9,93) vs 9,46 m (IC95% 6,8 m – 12,07); p:0,290], and OS: 11,53m (95% IC: 8,33 – 14,7) vs 18,9 m (IC 95% 13,3 – 24,5) p: 0,24. Lastly, response rate was also better for patients with HLA-B44 positive treated with PD1 monotherapy (66,7% vs 16,7% in HLA-B44 negative patients) p: 0,048, whilst when administering ICI combinations, HLA-B44 negative patients seemed to have a better response rate (44% vs 27% in HLA-B44 positive patients; p = 0,148). Conclusions: These results confirm in a prospective cohort the predictive impact of HLA-B44 supertype for patients treated with anti-PD(L)1 agent and suggest a potential benefit of combining checkpoint inhibitors in patients with other HLA supertypes (non-HLA-B44+).